147 related articles for article (PubMed ID: 25260450)
21. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
[TBL] [Abstract][Full Text] [Related]
22. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
23. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes.
Rice KR; Magers MJ; Beck SD; Cary KC; Einhorn LH; Ulbright TM; Foster RS
J Urol; 2014 Nov; 192(5):1403-9. PubMed ID: 24952240
[TBL] [Abstract][Full Text] [Related]
24. Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study.
Sun M; Abdollah F; Budaüs L; Liberman D; Tian Z; Morgan M; Johal R; Schmitges J; Shariat SF; Montorsi F; Greafen M; Perrotte P; Karakiewicz PI
Ann Surg Oncol; 2011 Oct; 18(10):2997-3004. PubMed ID: 21509630
[TBL] [Abstract][Full Text] [Related]
25. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
26. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
27. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection.
Ehrlich Y; Yossepowitch O; Kedar D; Baniel J
BJU Int; 2006 Jun; 97(6):1221-4. PubMed ID: 16686715
[TBL] [Abstract][Full Text] [Related]
28. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.
Sturgeon JF; Moore MJ; Kakiashvili DM; Duran I; Anson-Cartwright LC; Berthold DR; Warde PR; Gospodarowicz MK; Alison RE; Liu J; Ma C; Pond GR; Jewett MA
Eur Urol; 2011 Apr; 59(4):556-62. PubMed ID: 21190791
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors].
Dong P; Liu ZW; Li XD; Wu S; Li YH; Yao K; Qin ZK; Han H; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2013 Mar; 51(3):256-60. PubMed ID: 23859330
[TBL] [Abstract][Full Text] [Related]
30. Post-chemotherapy nerve-sparing retroperitoneal lymph node dissection for advanced germ cell tumor.
Miki T; Mizutani Y; Nakamura T; Kawauchi A; Nagahara A; Nonomura N; Okuyama A
Int J Urol; 2009 Apr; 16(4):379-82. PubMed ID: 19191930
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
32. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
Williams SB; Steele GS; Richie JP
J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
[TBL] [Abstract][Full Text] [Related]
33. Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?
Powles T
Hematol Oncol Clin North Am; 2011 Jun; 25(3):517-27,viii. PubMed ID: 21570606
[TBL] [Abstract][Full Text] [Related]
34. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
Carver BS; Serio AM; Bajorin D; Motzer RJ; Stasi J; Bosl GJ; Vickers AJ; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5603-8. PubMed ID: 17998544
[TBL] [Abstract][Full Text] [Related]
35. Adult primary pure teratoma of the testis. The Indiana experience.
Leibovitch I; Foster RS; Ulbright TM; Donohue JP
Cancer; 1995 May; 75(9):2244-50. PubMed ID: 7712432
[TBL] [Abstract][Full Text] [Related]
36. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
37. Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience.
Alanee SR; Carver BS; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2016 Sep; 95():128-31. PubMed ID: 27235751
[TBL] [Abstract][Full Text] [Related]
38. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.
Daugaard G; Gundgaard MG; Mortensen MS; Agerbæk M; Holm NV; Rørth M; von der Maase H; Christensen IJ; Lauritsen J
J Clin Oncol; 2014 Dec; 32(34):3817-23. PubMed ID: 25267754
[TBL] [Abstract][Full Text] [Related]
39. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
Nguyen CT; Stephenson AJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
[TBL] [Abstract][Full Text] [Related]
40. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
Yoon GH; Stein JP; Skinner DG
Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
